Ahmed Syed Minhaj Uddin, Jiang Zi Nong, Zheng Zhao Hong, Li Yulong, Wang Xiu Jun, Tang Xiuwen
Department of Biochemistry and Genetics, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058, P.R. China.
Department of Pathology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058, P.R. China.
Oncol Lett. 2019 Jan;17(1):773-780. doi: 10.3892/ol.2018.9705. Epub 2018 Nov 15.
Effective methods for predicting tumor response to preoperative chemotherapy are required. Aldo-ketoreductase family 1 member B10 (AKR1B10) is predominantly expressed in the gastrointestinal tract and serves an important function in cancer development and progression. The present study investigated whether AKR1B10 expression may predict the therapeutic response of locally advanced gastric cancer. A total of 53 patients with gastric cancer underwent neoadjuvant chemotherapy followed by surgery between January 2006 and December 2015. The protein expression level of AKR1B10 was determined in paraffin-embedded biopsy specimens using immunohistochemistry. Western blotting confirmed that the AKR1B10 protein is primarily localized to the cytoplasm. χ and Fisher's exact tests were used to determine the association of AKR1B10 with a number of clinic opathological features. Univariate and multivariate analyses were used to identify the prognostic factors. Survival rates were compared using Kaplan-Meier curves with a log-rank test. The positive rate of AKR1B10 protein expression was 58.5%, whereas 41.5% samples exhibited negative expression. The frequency of AKR1B10-positive gastric cancer samples was increased in patients with lymph node metastasis and decreased in those exhibiting tumor regression. The 5-years overall survival rate for the AKR1B10-positive group was significantly poorer than that for the AKR1B10-negative group. AKR1B10 expression was associated with lymph node metastasis and a poorer prognosis, along with a poor response to neoadjuvant chemotherapy suggesting that AKR1B10 may be a potential predictor for the therapeutic response of locally-advanced gastric cancer.
需要有效的方法来预测肿瘤对术前化疗的反应。醛酮还原酶家族1成员B10（AKR1B10）主要在胃肠道表达，在癌症发生和发展中起重要作用。本研究调查了AKR1B10表达是否可预测局部晚期胃癌的治疗反应。2006年1月至2015年12月期间，共有53例胃癌患者接受了新辅助化疗，随后接受了手术。使用免疫组织化学法在石蜡包埋的活检标本中测定AKR1B10的蛋白表达水平。蛋白质印迹法证实AKR1B10蛋白主要定位于细胞质。采用χ检验和Fisher精确检验来确定AKR1B10与多种临床病理特征的相关性。采用单因素和多因素分析来确定预后因素。使用Kaplan-Meier曲线和对数秩检验比较生存率。AKR1B10蛋白表达的阳性率为58.5%，而41.5%的样本呈阴性表达。AKR1B10阳性胃癌样本的频率在有淋巴结转移的患者中增加，而在出现肿瘤退缩的患者中降低。AKR1B10阳性组的5年总生存率明显低于AKR1B10阴性组。AKR1B10表达与淋巴结转移和较差的预后相关，同时对新辅助化疗反应不佳，提示AKR1B10可能是局部晚期胃癌治疗反应的潜在预测指标。
